Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback